FY2029 Earnings Forecast for HRMY Issued By HC Wainwright

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) – Stock analysts at HC Wainwright issued their FY2029 EPS estimates for Harmony Biosciences in a research report issued to clients and investors on Thursday, January 16th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of $5.99 per share for the year. HC Wainwright has a “Buy” rating and a $75.00 price target on the stock. The consensus estimate for Harmony Biosciences’ current full-year earnings is $2.43 per share.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same period in the prior year, the business posted $0.63 EPS. The firm’s quarterly revenue was up 16.0% on a year-over-year basis.

HRMY has been the subject of a number of other research reports. Mizuho increased their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Oppenheimer restated an “outperform” rating and set a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Raymond James reiterated an “outperform” rating and issued a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research note on Monday, January 13th. Finally, Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $55.00.

Harmony Biosciences Stock Performance

HRMY stock opened at $40.46 on Monday. Harmony Biosciences has a one year low of $28.14 and a one year high of $41.61. The firm has a market cap of $2.31 billion, a price-to-earnings ratio of 19.18, a PEG ratio of 0.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The firm has a 50-day simple moving average of $34.46 and a two-hundred day simple moving average of $34.96.

Hedge Funds Weigh In On Harmony Biosciences

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock valued at $31,000 after buying an additional 436 shares in the last quarter. Mendota Financial Group LLC raised its position in Harmony Biosciences by 24,125.0% during the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after acquiring an additional 965 shares during the period. CWM LLC lifted its holdings in Harmony Biosciences by 111.7% during the third quarter. CWM LLC now owns 1,469 shares of the company’s stock valued at $59,000 after purchasing an additional 775 shares in the last quarter. Quarry LP acquired a new stake in shares of Harmony Biosciences in the second quarter valued at about $62,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Harmony Biosciences during the third quarter worth about $74,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Insider Activity

In other news, insider Jeffrey Dierks sold 10,507 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $37.01, for a total transaction of $388,864.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 33,126 shares of company stock valued at $1,303,727 in the last quarter. 30.80% of the stock is currently owned by company insiders.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.